Focus: Pierre Fabre is a French specialty pharma company founded in 1962, headquartered in Aignan, with a focused portfolio in oncology and dermatology/cosmetics. The company operates with 247 active job openings and maintains a significant R&D pipeline.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Hot — 117 jobs added in 30d
Net +60 (117 new, 57 removed). Aggressive expansion phase.
Pierre Fabre is an acquisition or partnership target in waiting with deep scientific capabilities, but the near-term revenue cliff and single-product dependence make it a medium-risk career bet unless you prioritize early-stage oncology research over job security.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Pierre Fabre
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pierre Fabre's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Only marketed product and sole revenue driver; patent cliff in 2028 poses existential threat.
Established oncology standard-of-care drug; off-patent but maintains clinical relevance and pipeline expansion activities.
Generic chemotherapy with stable clinical use; represents mature, low-growth revenue segment.
Dental anesthetic with niche market; not central to company strategy.
2 discontinued, 0 duplicate formulations not shown
8-K Filing: Atara Biotherapeutics, Inc. (ATRA) (CIK 0001604464) — EX-99.1
EX-99.1
8-K Filing: Eton Pharmaceuticals, Inc. (ETON) (CIK 0001710340) — EXHIBIT 99.1 PRESS RELEASE RELATING TO HEMANGEOL LICENSING AGREEEMENT
EXHIBIT 99.1 PRESS RELEASE RELATING TO HEMANGEOL LICENSING AGREEEMENT
8-K Filing: Vyome Holdings, Inc (HIND) (CIK 0001427570) — PRODUCT ASSESSMENT AND VALUATION REPORT
PRODUCT ASSESSMENT AND VALUATION REPORT
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo